

Company Profile

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Executive Board



Matthias Gärtner,
CEO



Falk Neukirch,
CFO



Mi-Young Miehler,
COO



Christoph PruBeit,
CINO




Constantijn van Rietschoten,
CIM


Structure and Segments

PHARMACEUTICAL SUPPLY	
<ul style="list-style-type: none"> Highly focused on Specialty Pharma drugs 1,000 products available 	
PATIENT-SPECIFIC THERAPIES	
<ul style="list-style-type: none"> Strongly positioned in patient-specific medication >1m individualized preparations in FY¹ 2024 	
INTERNATIONAL BUSINESS	
<ul style="list-style-type: none"> Leading full-service compounding services platform 	


FY¹ 2024 EBITDA pre* split²



Consolidated Revenue in €m



Consolidated EBITDA pre* in €m



¹ Full Year; ² Including the segment "Services" (-13% in FY 2024); * adjusted for extraordinary expenses (EBITDA pre); CAGR = Compound Annual Growth Rate.

Contact:
ir@medios.group
www.medios.group

Key Figures

in €m	2024 (IFRS)	2023 (IFRS)	Change
Revenue	1,883.0	1,784.7	+5.5%
EBITDA pre*	79.0	60.5	+30.5%
Margin in %	4.2	3.4	+23.5%

*adjusted for extraordinary expenses

Basic Information

Share Capital	€25,505,723
No. of shares	25,505,723
Share class	No-par value bearer shares
WKN/ISIN	A1MMCC/DE000A1MMCC8 / DE000A409682*
Trading places	Regulated Market Frankfurt (Prime Standard)

* Note pursuant to Sec. 7 German Stock Exchange Admission Regulation (Börsenzulassungsverordnung – BörsZulV): From a capital increase in kind registered with the commercial register on June 11, 2024, 1,700,000 newly issued shares came into existence, which bear a separate ISIN (DE000A409682) and are currently not admitted to trading.


Shareholder Structure

All figures according to voting rights notifications of the notifying parties

58.5%

Free float

- 4.9% Paladin Asset Management investment stock corporation with variable capital and sub-funds
- 4.7% SEB Investment Management AB



19.7%

Martin Hesse

incl. attribution of
BMSH GmbH

15.1%

Luxempart Invest S.á.r.l.

6.7%

Bencis Capital Partners B.V.

Share Price in €

